← All trials
NCT04674826
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 8, 2021
- Primary completion
- Dec 28, 2021
- Completion date
- Dec 28, 2021
- First posted
- Dec 19, 2020
- Last posted
- Nov 11, 2021
- Enrollment
- 101
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Leo PharmaLead sponsor
- Leo PharmaStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.